Synthego debuts CRISPR-based cell engineering platform

By The Science Advisory Board staff writers

April 7, 2021 -- Synthego has launched Eclipse, a high-throughput, CRISPR-based cell engineering platform aimed at accelerating drug discovery and validation.

The Eclipse platform is scalable and aims to enhance disease modeling and drug target identification and validation, and to accelerate cell therapy manufacturing. Eclipse uses machine learning combined with automation to make edits across hundreds of cell types.

Synthego's Eclipse platform enables scalable CRISPR-based cell engineering. Image courtesy of Synthego.

The platform is engineered to use a cell-type agnostic process and aims to benefit researchers working with induced pluripotent stem (iPS) cells and immortalized cell lines.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?